Endoglycosidase [EPC]

Endoglycosidase [EPC] was reported 1853 times

Drugs of the Endoglycosidase [EPC] class are most commonly taken among patients reporting these side effects:

# Drug class Count Frequency
0 GRIP STRENGTH 107 0.4672
1 MODIFIED RADICAL MASTECTOMY 19 0.3276
2 SWOLLEN JOINT COUNT 62 0.2480
3 AXILLARY LYMPHADENECTOMY 16 0.2051
4 PURTSCHER RETINOPATHY 16 0.1951
5 ADMINISTRATION RELATED REACTION 29 0.1487
6 SLEEP DISORDER DUE TO GENERAL MEDICAL CONDITION, HYPERSOMNIA TYPE 15 0.1429
7 DEEP VEIN THROMBOSIS POSTOPERATIVE 239 0.1193
8 PAROPHTHALMIA 27 0.1134
9 LUPUS VULGARIS 136 0.1079
10 TENDER JOINT COUNT 9 0.1071
11 POLYNEUROPATHY CHRONIC 7 0.1029
12 PORPHYRIA ACUTE 136 0.0948
13 C-REACTIVE PROTEIN 87 0.0939
14 ACUTE MACULAR NEURORETINOPATHY 15 0.0877
15 X-RAY ABNORMAL 154 0.0860
16 ACQUIRED PORPHYRIA 6 0.0845
17 RETINITIS 140 0.0810
18 ADJUSTMENT DISORDER WITH DEPRESSED MOOD 158 0.0762
19 ELECTROCARDIOGRAM T WAVE AMPLITUDE INCREASED 7 0.0745
20 ADMINISTRATION SITE REACTION 26 0.0674
21 SWOLLEN JOINT COUNT INCREASED 204 0.0639
22 DISLOCATION OF VERTEBRA 145 0.0635
23 FACET JOINT SYNDROME 205 0.0629
24 LAGOPHTHALMOS 21 0.0513
25 RHEUMATIC FEVER 219 0.0491
26 PERIPHERAL VENOUS DISEASE 200 0.0489
27 ANTIPHOSPHOLIPID ANTIBODIES 9 0.0462
28 OPEN GLOBE INJURY 7 0.0424
29 BREAST OPERATION 34 0.0416
30 BONE EROSION 142 0.0401
31 PROCEDURAL HEADACHE 16 0.0390
32 C-REACTIVE PROTEIN ABNORMAL 240 0.0374
33 ADMINISTRATION SITE PAIN 43 0.0373
34 SLEEP DISORDER DUE TO GENERAL MEDICAL CONDITION, INSOMNIA TYPE 229 0.0352
35 DUODENAL ULCER PERFORATION 262 0.0352
36 RHEUMATOID FACTOR POSITIVE 202 0.0349
37 HYPOCHOLESTEROLAEMIA 12 0.0340
38 ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODY POSITIVE 240 0.0335
39 DRUG TOLERANCE DECREASED 92 0.0327
40 BREAST CONSERVING SURGERY 16 0.0312
41 INTRAOCULAR PRESSURE FLUCTUATION 6 0.0305
42 ADMINISTRATION SITE SWELLING 9 0.0277
43 MUSCLE INJURY 228 0.0275
44 SKIN LAXITY 12 0.0274
45 CONJUNCTIVAL OEDEMA 28 0.0272
46 AUTOIMMUNE DISORDER 265 0.0272
47 HELICOBACTER INFECTION 268 0.0260
48 ADMINISTRATION SITE ERYTHEMA 7 0.0246
49 BREAST CANCER STAGE III 157 0.0242
50 FOLLICULITIS 254 0.0242
51 LIGHT CHAIN ANALYSIS ABNORMAL 5 0.0240
52 LIP DRY 213 0.0234
53 MATERNAL EXPOSURE TIMING UNSPECIFIED 82 0.0218
54 MASTECTOMY 37 0.0211
55 BURSITIS 245 0.0202
56 DIFFUSE LARGE B-CELL LYMPHOMA REFRACTORY 19 0.0201
57 INJECTION RELATED REACTION 33 0.0200
58 ORBITAL OEDEMA 10 0.0198
59 HAND DEFORMITY 248 0.0189
60 CELLULITIS ORBITAL 11 0.0189
61 INTERCEPTED PRODUCT STORAGE ERROR 66 0.0185
62 PEMPHIGUS 224 0.0179
63 MYASTHENIA GRAVIS CRISIS 25 0.0169
64 GRIP STRENGTH DECREASED 146 0.0166
65 ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODY 11 0.0165
66 MYOPATHY TOXIC 10 0.0162
67 JOINT RANGE OF MOTION DECREASED 209 0.0156
68 CELLULITE 5 0.0153
69 CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY 22 0.0153
70 LUPUS-LIKE SYNDROME 138 0.0152
71 WOUND INFECTION 166 0.0151
72 FACIAL WASTING 4 0.0149
73 EXOSTOSIS 133 0.0145
74 SUBCUTANEOUS DRUG ABSORPTION IMPAIRED 8 0.0143
75 SCIATICA 223 0.0140
76 HYPERCHOLESTEROLAEMIA 135 0.0140
77 AXILLARY VEIN THROMBOSIS 5 0.0135
78 PERICARDITIS 226 0.0134
79 LID SULCUS DEEPENED 5 0.0134
80 WALKING AID USER 86 0.0130
81 OBESITY 199 0.0125
82 PROCEDURAL DIZZINESS 4 0.0124
83 LOCAL ANAESTHETIC SYSTEMIC TOXICITY 13 0.0122
84 LOCAL REACTION 9 0.0121
85 SYNOVITIS 216 0.0120
86 LOWER LIMB FRACTURE 230 0.0120
87 FOOT DEFORMITY 129 0.0116
88 EXOPHTHALMOS 25 0.0116
89 GLOSSODYNIA 241 0.0108
90 HER2 POSITIVE BREAST CANCER 4 0.0107
91 SERONEGATIVE ARTHRITIS 12 0.0105
92 JOINT DESTRUCTION 16 0.0103
93 METASTATIC LYMPHOMA 4 0.0102
94 FIBROMYALGIA 244 0.0100
95 IRRITABLE BOWEL SYNDROME 213 0.0099
96 INVASIVE BREAST CARCINOMA 4 0.0097
97 HEART FAILURE WITH REDUCED EJECTION FRACTION 5 0.0093
98 GRANULOCYTE COUNT DECREASED 17 0.0092
99 PRODUCT CLOSURE ISSUE 5 0.0090
100 BREAST NEOPLASM 9 0.0087
101 MYASTHENIA GRAVIS 70 0.0087
102 LIVER INJURY 208 0.0085
103 PULMONARY FIBROSIS 160 0.0083
104 CONGENITAL ANOMALY 63 0.0081
105 RED BLOOD CELL SEDIMENTATION RATE INCREASED 90 0.0081
106 WOUND 226 0.0081
107 HEPATIC CIRRHOSIS 150 0.0080
108 DILATED CARDIOMYOPATHY 8 0.0079
109 HIP ARTHROPLASTY 121 0.0079
110 JOINT DISLOCATION 81 0.0077
111 SLEEP DISORDER DUE TO A GENERAL MEDICAL CONDITION 129 0.0076
112 TYPE 2 DIABETES MELLITUS 254 0.0075
113 IMPAIRED HEALING 237 0.0072
114 STEM CELL TRANSPLANT 18 0.0072
115 INCORRECT ROUTE OF PRODUCT ADMINISTRATION 120 0.0070
116 SYSTEMIC LUPUS ERYTHEMATOSUS 246 0.0069
117 PARONYCHIA 30 0.0068
118 LIGHT CHAIN ANALYSIS INCREASED 7 0.0068
119 RETINAL ARTERY OCCLUSION 17 0.0067
120 NIGHT SWEATS 213 0.0066
121 LIVE BIRTH 55 0.0066
122 CAUDA EQUINA SYNDROME 5 0.0065
123 ANAESTHETIC COMPLICATION 17 0.0063
124 TRANSPLANT 15 0.0063
125 PRESCRIBED OVERDOSE 121 0.0062
126 NODULAR REGENERATIVE HYPERPLASIA 4 0.0062
127 WEIGHT FLUCTUATION 65 0.0062
128 BLOOD CHOLESTEROL INCREASED 280 0.0060
129 INJECTION SITE EXFOLIATION 4 0.0060
130 PREGNANCY 118 0.0059
131 NO ADVERSE EVENT 1064 0.0059
132 KNEE ARTHROPLASTY 123 0.0058
133 INFUSION RELATED REACTION 387 0.0058
134 ROAD TRAFFIC ACCIDENT 244 0.0058
135 LOWER RESPIRATORY TRACT INFECTION 265 0.0058
136 INFUSION SITE REACTION 17 0.0057
137 OSTEOARTHRITIS 236 0.0056
138 OPTIC ATROPHY 9 0.0055
139 TOXIC ANTERIOR SEGMENT SYNDROME 6 0.0055
140 BLOOD PHOSPHORUS INCREASED 15 0.0055
141 EAR INFECTION 143 0.0054
142 PSORIATIC ARTHROPATHY 216 0.0053
143 LIVER DISORDER 234 0.0053
144 FREQUENT BOWEL MOVEMENTS 142 0.0053
145 ASPARTATE AMINOTRANSFERASE ABNORMAL 8 0.0052
146 BLOOD IMMUNOGLOBULIN G DECREASED 13 0.0052
147 ONYCHOMADESIS 22 0.0052
148 SKIN TEXTURE ABNORMAL 5 0.0052
149 STOMATITIS 316 0.0052
150 DELIRIUM 179 0.0052
151 LYMPHADENECTOMY 5 0.0051
152 PRODUCT TEMPERATURE EXCURSION ISSUE 26 0.0051
153 DISCOMFORT 308 0.0050
154 PROCEDURAL NAUSEA 4 0.0050
155 GAIT INABILITY 166 0.0050
156 METASTASES TO CENTRAL NERVOUS SYSTEM 63 0.0049
157 METASTASES TO SKIN 5 0.0048
158 ARTHROPATHY 269 0.0048
159 BLISTER 271 0.0048
160 RESPIRATORY DISORDER 143 0.0048
161 LUNG DISORDER 232 0.0047
162 CARDIAC DYSFUNCTION 17 0.0046
163 PROTEIN TOTAL DECREASED 17 0.0045
164 INDURATION 8 0.0045
165 BLEPHAROSPASM 28 0.0044
166 STRABISMUS 13 0.0044
167 ANAESTHETIC COMPLICATION NEUROLOGICAL 4 0.0044
168 HEPATIC ENZYME INCREASED 301 0.0044
169 LABORATORY TEST ABNORMAL 130 0.0044
170 MUSCLE SWELLING 4 0.0043
171 DIFFUSE ALVEOLAR DAMAGE 5 0.0043
172 INTERCEPTED MEDICATION ERROR 20 0.0043
173 MUSCULOSKELETAL PAIN 225 0.0043
174 EYE INJURY 13 0.0043
175 WHITE BLOOD CELL COUNT INCREASED 162 0.0042
176 RECTAL HAEMORRHAGE 181 0.0042
177 BREAST CANCER STAGE II 35 0.0042
178 ILL-DEFINED DISORDER 255 0.0042
179 FOREIGN BODY IN EYE 4 0.0042
180 INFLAMMATION 207 0.0040
181 PLASMA CELL MYELOMA RECURRENT 13 0.0040
182 ONYCHALGIA 4 0.0040
183 OEDEMA 216 0.0040
184 ULCER HAEMORRHAGE 26 0.0038
185 OPHTHALMOPLEGIA 6 0.0038
186 EJECTION FRACTION DECREASED 59 0.0038
187 INJECTION SITE REACTION 258 0.0037
188 OPTIC NERVE DISORDER 6 0.0037
189 PLASMA CELL MYELOMA REFRACTORY 5 0.0037
190 NAIL DISORDER 32 0.0037
191 IMMUNOGLOBULINS DECREASED 5 0.0036
192 WHEEZING 215 0.0036
193 JOINT STIFFNESS 95 0.0036
194 COLITIS ULCERATIVE 161 0.0036
195 MOBILITY DECREASED 256 0.0036
196 CONTUSION 341 0.0035
197 SWELLING 327 0.0035
198 C-REACTIVE PROTEIN INCREASED 127 0.0035
199 NAIL INFECTION 5 0.0035
200 BREAST CANCER RECURRENT 11 0.0035
201 INVESTIGATION ABNORMAL 5 0.0035
202 CONTRAINDICATED PRODUCT ADMINISTERED 105 0.0035
203 OPTIC NERVE INJURY 4 0.0034
204 BREAST DISORDER 7 0.0034
205 IMMUNODEFICIENCY 50 0.0034
206 INVASIVE DUCTAL BREAST CARCINOMA 9 0.0033
207 HYPOALBUMINAEMIA 25 0.0032
208 RECURRENT CANCER 13 0.0032
209 OSTEOPOROSIS 130 0.0032
210 DRY MOUTH 255 0.0031
211 PHYSICAL DECONDITIONING 8 0.0031
212 IATROGENIC INJURY 4 0.0031
213 INTERCEPTED PRODUCT SELECTION ERROR 4 0.0031
214 NAIL DISCOLOURATION 12 0.0030
215 THERAPY CHANGE 30 0.0030
216 GASTROINTESTINAL DISORDER 273 0.0030
217 PHARYNGEAL ULCERATION 4 0.0030
218 INJURY 207 0.0029
219 LYMPHOEDEMA 20 0.0029
220 DEATH NEONATAL 4 0.0029
221 JOINT INSTABILITY 4 0.0029
222 INFUSION SITE PRURITUS 9 0.0028
223 POLYARTHRITIS 15 0.0028
224 MATERNAL EXPOSURE DURING PREGNANCY 251 0.0028
225 SINUSITIS 288 0.0028
226 HYPERNATRAEMIA 14 0.0028
227 BRAIN FOG 44 0.0028
228 METASTATIC NEOPLASM 12 0.0028
229 PRESCRIBED UNDERDOSE 55 0.0028
230 AMNESIA 179 0.0027
231 MUSCULOSKELETAL STIFFNESS 240 0.0027
232 HYPERTRANSAMINASAEMIA 19 0.0027
233 PANCREATITIS 143 0.0027
234 EYELID PTOSIS 27 0.0027
235 BONE MARROW TRANSPLANT 5 0.0026
236 LICHEN PLANUS 6 0.0026
237 ASTHMA 286 0.0025
238 FEELING HOT 152 0.0025
239 EAR PAIN 48 0.0025
240 SPINAL FUSION SURGERY 10 0.0025
241 CYTOPENIA 30 0.0024
242 PRODUCT PREPARATION ISSUE 16 0.0024
243 SKIN ATROPHY 14 0.0024
244 VENOUS THROMBOSIS LIMB 5 0.0024
245 ELECTROCARDIOGRAM ST SEGMENT ELEVATION 8 0.0024
246 MYELOSUPPRESSION 87 0.0024
247 HYPOAESTHESIA 357 0.0024
248 BREAST MASS 16 0.0024
249 DRUG TOLERANCE 12 0.0024
250 OPTIC NEUROPATHY 5 0.0024
251 SENSORY LOSS 19 0.0024
252 PLASMA CELL MYELOMA 92 0.0024
253 LOWER RESPIRATORY TRACT CONGESTION 4 0.0024
254 GENERAL PHYSICAL HEALTH DETERIORATION 270 0.0023
255 THERAPY NON-RESPONDER 104 0.0023
256 MASTICATION DISORDER 7 0.0023
257 CATATONIA 12 0.0023
258 GINGIVAL SWELLING 10 0.0023
259 NEUROPATHY PERIPHERAL 213 0.0022
260 DRUG MONITORING PROCEDURE NOT PERFORMED 4 0.0022
261 BONE LESION 8 0.0022
262 SKIN WRINKLING 6 0.0022
263 VASCULAR DEVICE INFECTION 10 0.0022
264 PRODUCT ADMINISTERED AT INAPPROPRIATE SITE 40 0.0022
265 SYMPTOM RECURRENCE 13 0.0022
266 VITREOUS HAEMORRHAGE 6 0.0022
267 MUSCULAR WEAKNESS 244 0.0021
268 THERAPEUTIC PRODUCT EFFECT DECREASED 96 0.0021
269 RHEUMATOID ARTHRITIS 242 0.0021
270 NEUTROPHIL COUNT ABNORMAL 6 0.0021
271 BACK INJURY 23 0.0021
272 PRODUCT STORAGE ISSUE 8 0.0021
273 RESPIRATORY SYMPTOM 6 0.0021
274 LYMPHADENOPATHY MEDIASTINAL 4 0.0021
275 GINGIVAL RECESSION 4 0.0021
276 TASTE DISORDER 42 0.0021
277 ABDOMINAL DISCOMFORT 347 0.0021
278 PRODUCT PACKAGING CONFUSION 5 0.0021
279 ARTHRITIS 161 0.0020
280 INJECTION SITE DISCHARGE 11 0.0020
281 HAEMATOLOGICAL INFECTION 5 0.0020
282 PUSTULAR PSORIASIS 7 0.0020
283 JOINT SWELLING 243 0.0020
284 INTENTIONAL PRODUCT USE ISSUE 175 0.0020
285 CARDIAC DISCOMFORT 4 0.0020
286 PLATELET DISORDER 5 0.0020
287 INFECTION 285 0.0020
288 SLEEP DISORDER 136 0.0019
289 SPONDYLITIS 7 0.0019
290 INJECTION SITE DISCOMFORT 20 0.0019
291 IRIDOCYCLITIS 6 0.0019
292 HYPERSENSITIVITY 352 0.0019
293 PERIPHERAL SWELLING 292 0.0019
294 VASCULAR OCCLUSION 4 0.0019
295 PRODUCT INEFFECTIVE FOR UNAPPROVED USE 5 0.0019
296 HYPOVOLAEMIC SHOCK 9 0.0019
297 PROTEIN TOTAL INCREASED 5 0.0019
298 ALOPECIA 366 0.0019
299 CONFUSIONAL STATE 300 0.0019
300 DRUG INTOLERANCE 179 0.0019
301 INFUSION SITE BRUISING 4 0.0019
302 ORAL FUNGAL INFECTION 5 0.0018
303 MIGRAINE 173 0.0018
304 NASOPHARYNGITIS 330 0.0018
305 METASTASES TO SPINE 6 0.0018
306 PARAESTHESIA 279 0.0018
307 SUSPECTED OFF LABEL USE 8 0.0018
308 METASTASES TO BONE 29 0.0018
309 OFF LABEL USE 1535 0.0018
310 LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES 84 0.0017
311 DENGUE FEVER 4 0.0017
312 EYELID DISORDER 4 0.0017
313 ADRENAL INSUFFICIENCY 21 0.0017
314 DECREASED APPETITE 401 0.0017
315 DYSPNOEA AT REST 5 0.0017
316 PRODUCT LABEL CONFUSION 10 0.0017
317 HAEMORRHAGE SUBCUTANEOUS 6 0.0017
318 HYPERTENSION 358 0.0017
319 URTICARIA 281 0.0017
320 DYSPEPSIA 164 0.0017
321 INJECTION SITE RASH 51 0.0017
322 RASH VESICULAR 8 0.0017
323 HYPERPYREXIA 7 0.0017
324 EMBOLISM VENOUS 5 0.0016
325 DERMATITIS ACNEIFORM 10 0.0016
326 BLOOD PHOSPHORUS DECREASED 6 0.0016
327 SENSORY DISTURBANCE 26 0.0016
328 HORDEOLUM 7 0.0016
329 EYE MOVEMENT DISORDER 11 0.0016
330 MEMORY IMPAIRMENT 220 0.0016
331 DISEASE PROGRESSION 188 0.0016
332 CHEST PAIN 294 0.0016
333 IMMUNOSUPPRESSION 14 0.0016
334 MUSCLE SPASMS 291 0.0016
335 PRODUCT ADMINISTRATION ERROR 32 0.0016
336 ESCHERICHIA INFECTION 13 0.0016
337 CONJUNCTIVAL HAEMORRHAGE 6 0.0016
338 RASH 666 0.0015
339 INJECTION SITE DISCOLOURATION 19 0.0015
340 MEDICATION ERROR 83 0.0015
341 ABDOMINAL PAIN UPPER 307 0.0015
342 PYREXIA 515 0.0015
343 NEUTROPHIL COUNT INCREASED 15 0.0015
344 OEDEMA PERIPHERAL 178 0.0015
345 TYPE IV HYPERSENSITIVITY REACTION 4 0.0015
346 RHINALGIA 4 0.0015
347 FUNCTIONAL GASTROINTESTINAL DISORDER 5 0.0014
348 INJECTION SITE ERYTHEMA 179 0.0014
349 INFUSION SITE SWELLING 9 0.0014
350 ASTHENIA 537 0.0014
351 EAR PRURITUS 5 0.0014
352 MUSCLE FATIGUE 6 0.0014
353 ABDOMINAL TENDERNESS 7 0.0014
354 INTRAOCULAR PRESSURE INCREASED 18 0.0014
355 DIARRHOEA 909 0.0014
356 ADVERSE EVENT 129 0.0014
357 SURGERY 82 0.0014
358 BREAST CANCER METASTATIC 15 0.0014
359 BLOOD ALBUMIN DECREASED 11 0.0014
360 TREATMENT FAILURE 112 0.0014
361 LIVER FUNCTION TEST INCREASED 29 0.0013
362 VISUAL IMPAIRMENT 167 0.0013
363 HICCUPS 11 0.0013
364 MYOSITIS 12 0.0013
365 POLYNEUROPATHY 16 0.0013
366 METASTASES TO LYMPH NODES 9 0.0013
367 PAPILLOEDEMA 6 0.0013
368 FULL BLOOD COUNT ABNORMAL 14 0.0013
369 INJECTION SITE VESICLES 8 0.0013
370 FACE INJURY 5 0.0013
371 ONYCHOCLASIS 9 0.0013
372 NEOPLASM 15 0.0013
373 RECTAL CANCER 4 0.0013
374 INJECTION SITE PAIN 397 0.0013
375 FACIAL PARALYSIS 11 0.0013
376 MASS 18 0.0013
377 NORMAL NEWBORN 7 0.0013
378 PERFORMANCE STATUS DECREASED 6 0.0013
379 NEUTROPHIL COUNT DECREASED 52 0.0013
380 PNEUMONIA VIRAL 4 0.0013
381 AGEUSIA 31 0.0012
382 CARDIOTOXICITY 11 0.0012
383 MUCOSAL INFLAMMATION 32 0.0012
384 WEIGHT INCREASED 273 0.0012
385 SKIN REACTION 17 0.0012
386 EYELID OEDEMA 14 0.0012
387 STRESS CARDIOMYOPATHY 7 0.0012
388 BLOOD UREA INCREASED 20 0.0012
389 CHILLS 140 0.0012
390 DIPLOPIA 31 0.0012
391 WHITE BLOOD CELL COUNT DECREASED 129 0.0012
392 PRODUCT PRESCRIBING ERROR 28 0.0012
393 INCORRECT DRUG ADMINISTRATION RATE 5 0.0012
394 NERVE INJURY 13 0.0012
395 DISABILITY 23 0.0012
396 TEMPERATURE INTOLERANCE 12 0.0012
397 ADVERSE DRUG REACTION 104 0.0012
398 PERIORBITAL OEDEMA 6 0.0012
399 HYPOPNOEA 4 0.0012
400 SUPRAVENTRICULAR TACHYCARDIA 11 0.0011
401 PRURITUS 439 0.0011
402 ONYCHOMYCOSIS 5 0.0011
403 LYMPHOPENIA 16 0.0011
404 UPPER RESPIRATORY TRACT INFECTION 52 0.0011
405 METASTASIS 8 0.0011
406 FATIGUE 861 0.0011
407 HYPOKALAEMIA 51 0.0011
408 PNEUMONITIS 30 0.0011
409 BLOOD PRESSURE SYSTOLIC DECREASED 5 0.0011
410 HAEMOGLOBIN INCREASED 5 0.0011
411 THERAPEUTIC PRODUCT EFFECT DELAYED 5 0.0011
412 RETINAL DETACHMENT 10 0.0011
413 PRODUCT STORAGE ERROR 95 0.0011
414 SENSITIVE SKIN 8 0.0011
415 AMYLASE INCREASED 4 0.0011
416 METASTASES TO LIVER 19 0.0011
417 WEIGHT DECREASED 301 0.0011
418 PLATELET COUNT DECREASED 114 0.0011
419 PRODUCT LEAKAGE 6 0.0011
420 INFUSION SITE ERYTHEMA 9 0.0011
421 SKIN TIGHTNESS 5 0.0011
422 SKIN TOXICITY 6 0.0011
423 PERIORBITAL SWELLING 6 0.0011
424 SKIN ABRASION 5 0.0011
425 PERONEAL NERVE PALSY 6 0.0011
426 SKIN DISORDER 35 0.0010
427 INSOMNIA 279 0.0010
428 CYTOKINE RELEASE SYNDROME 21 0.0010
429 GASTRIC INFECTION 4 0.0010
430 TUMOUR MARKER INCREASED 5 0.0010
431 ANXIETY 296 0.0010
432 OPTIC ISCHAEMIC NEUROPATHY 4 0.0010
433 REHABILITATION THERAPY 4 0.0010
434 FINGER DEFORMITY 5 0.0010
435 ARTHRALGIA 428 0.0010
436 MUSCLE ATROPHY 13 0.0010
437 EPIGASTRIC DISCOMFORT 4 0.0010
438 COELIAC DISEASE 10 0.0010
439 MALAISE 445 0.0010
440 CONDITION AGGRAVATED 308 0.0010
441 GAIT DISTURBANCE 193 0.0010
442 MUSCLE TWITCHING 23 0.0010
443 EXPOSURE DURING PREGNANCY 62 0.0010
444 MOUTH ULCERATION 21 0.0010
445 PNEUMONIA 321 0.0010
446 FUNGAL SKIN INFECTION 4 0.0010
447 PULMONARY TOXICITY 7 0.0010
448 THERMAL BURN 7 0.0010
449 IMMUNE SYSTEM DISORDER 13 0.0010
450 NEUTROPENIA 132 0.0010
451 POOR VENOUS ACCESS 10 0.0010
452 PAIN 591 0.0010
453 LIQUID PRODUCT PHYSICAL ISSUE 7 0.0010
454 ERYTHEMA 197 0.0010
455 TACHYPNOEA 13 0.0010
456 METASTASES TO LUNG 11 0.0010
457 NEOPLASM PROGRESSION 33 0.0009
458 ENTERITIS 6 0.0009
459 PAIN IN EXTREMITY 275 0.0009
460 COMPRESSION FRACTURE 5 0.0009
461 DEPRESSION 212 0.0009
462 INFUSION SITE PAIN 12 0.0009
463 BLOOD POTASSIUM DECREASED 28 0.0009
464 OXYGEN SATURATION DECREASED 52 0.0009
465 VOMITING 435 0.0009
466 PRODUCT PREPARATION ERROR 19 0.0009
467 ASCITES 27 0.0009
468 TONGUE DISCOLOURATION 4 0.0009
469 SYRINGE ISSUE 16 0.0009
470 NECK PAIN 51 0.0009
471 NONSPECIFIC REACTION 5 0.0009
472 ABDOMINAL ABSCESS 4 0.0009
473 CARDIAC FAILURE ACUTE 6 0.0009
474 DIZZINESS 449 0.0009
475 MENINGITIS 6 0.0009
476 PRODUCT DOSE OMISSION ISSUE 264 0.0009
477 THERAPY PARTIAL RESPONDER 14 0.0009
478 LEFT VENTRICULAR DYSFUNCTION 6 0.0009
479 PRODUCT USE ISSUE 168 0.0009
480 SKIN DISCOLOURATION 41 0.0009
481 SKIN INFECTION 10 0.0009
482 IRON DEFICIENCY 4 0.0009
483 POST PROCEDURAL COMPLICATION 17 0.0009
484 DYSPNOEA 501 0.0009
485 CENTRAL NERVOUS SYSTEM LESION 12 0.0009
486 PRODUCT DISPENSING ERROR 19 0.0009
487 PNEUMONIA BACTERIAL 8 0.0009
488 INTERSTITIAL LUNG DISEASE 42 0.0009
489 ENTEROCOLITIS 5 0.0009
490 RENAL FUNCTION TEST ABNORMAL 4 0.0009
491 DRUG-INDUCED LIVER INJURY 27 0.0009
492 DEFORMITY 8 0.0009
493 PERIPHERAL SENSORY NEUROPATHY 5 0.0009
494 LYMPHADENOPATHY 30 0.0008
495 BLOOD ALKALINE PHOSPHATASE INCREASED 21 0.0008
496 DEVICE RELATED INFECTION 13 0.0008
497 COLITIS MICROSCOPIC 4 0.0008
498 FULL BLOOD COUNT DECREASED 17 0.0008
499 VISUAL ACUITY REDUCED 28 0.0008
500 RETINAL HAEMORRHAGE 6 0.0008
501 CELLULITIS 42 0.0008
502 ADVERSE REACTION 11 0.0008
503 CLOSTRIDIUM DIFFICILE INFECTION 18 0.0008
504 ASPIRATION 9 0.0008
505 HAEMOGLOBIN DECREASED 84 0.0008
506 EPILEPSY 25 0.0008
507 PHARYNGEAL SWELLING 8 0.0008
508 PRODUCT CONTAINER ISSUE 7 0.0008
509 BLOOD BILIRUBIN INCREASED 22 0.0008
510 CARDIOMYOPATHY 12 0.0008
511 CEREBRAL DISORDER 6 0.0008
512 PIGMENTATION DISORDER 5 0.0008
513 ORGANISING PNEUMONIA 4 0.0008
514 RESPIRATORY SYNCYTIAL VIRUS INFECTION 7 0.0008
515 INJECTION SITE INFLAMMATION 4 0.0008
516 THROAT IRRITATION 36 0.0008
517 THROMBOCYTOPENIA 89 0.0008
518 ABDOMINAL PAIN 185 0.0008
519 KLEBSIELLA INFECTION 4 0.0008
520 HEPATIC CYTOLYSIS 10 0.0008
521 PRESYNCOPE 19 0.0008
522 VIRAL INFECTION 26 0.0008
523 BLOOD CREATININE INCREASED 51 0.0008
524 HAEMOGLOBIN ABNORMAL 5 0.0008
525 APHTHOUS ULCER 6 0.0008
526 CHOKING 15 0.0008
527 HYPOGAMMAGLOBULINAEMIA 5 0.0008
528 LEUKOPENIA 38 0.0008
529 SARS-COV-2 TEST POSITIVE 10 0.0008
530 FURUNCLE 6 0.0008
531 RASH PRURITIC 41 0.0008
532 BURNING SENSATION 53 0.0008
533 CLOSTRIDIUM DIFFICILE COLITIS 8 0.0008
534 SKIN MASS 5 0.0007
535 INJECTION SITE SWELLING 57 0.0007
536 POSTOPERATIVE WOUND INFECTION 5 0.0007
537 THROAT TIGHTNESS 20 0.0007
538 HEADACHE 463 0.0007
539 HAEMATOTOXICITY 7 0.0007
540 RED BLOOD CELL COUNT DECREASED 21 0.0007
541 MATERNAL EXPOSURE BEFORE PREGNANCY 5 0.0007
542 HYPOAESTHESIA ORAL 11 0.0007
543 UPPER-AIRWAY COUGH SYNDROME 6 0.0007
544 ILLNESS 75 0.0007
545 OSTEOPENIA 11 0.0007
546 THROMBOTIC MICROANGIOPATHY 7 0.0007
547 HAEMORRHOIDS 14 0.0007
548 DYSARTHRIA 27 0.0007
549 COLITIS 27 0.0007
550 MYDRIASIS 9 0.0007
551 SCAB 8 0.0007
552 BLOOD MAGNESIUM DECREASED 6 0.0007
553 PARAESTHESIA ORAL 10 0.0007
554 VISUAL FIELD DEFECT 5 0.0007
555 FEEDING DISORDER 14 0.0007
556 FAECES SOFT 5 0.0007
557 SKIN WARM 4 0.0007
558 OSTEONECROSIS OF JAW 17 0.0007
559 MOTOR DYSFUNCTION 7 0.0007
560 TACHYCARDIA 61 0.0007
561 BODY TEMPERATURE INCREASED 14 0.0007
562 SPINAL PAIN 8 0.0007
563 TUMOUR LYSIS SYNDROME 6 0.0007
564 HYPERCHLORHYDRIA 4 0.0007
565 BACK DISORDER 11 0.0007
566 TREATMENT NONCOMPLIANCE 37 0.0007
567 GASTROINTESTINAL INFECTION 6 0.0007
568 SNEEZING 15 0.0007
569 INJECTION SITE BRUISING 53 0.0007
570 URINARY TRACT INFECTION 113 0.0007
571 OPTIC NEURITIS 6 0.0007
572 NEURALGIA 16 0.0007
573 TROPONIN INCREASED 5 0.0007
574 INSURANCE ISSUE 10 0.0007
575 BRAIN NEOPLASM 6 0.0007
576 INTERCEPTED PRODUCT ADMINISTRATION ERROR 5 0.0007
577 MUSCLE SPASTICITY 8 0.0007
578 MENISCUS INJURY 4 0.0006
579 IRON DEFICIENCY ANAEMIA 6 0.0006
580 INTERCEPTED PRODUCT PREPARATION ERROR 8 0.0006
581 RHINORRHOEA 42 0.0006
582 INJECTION SITE EXTRAVASATION 8 0.0006
583 FEBRILE NEUTROPENIA 43 0.0006
584 CONCOMITANT DISEASE AGGRAVATED 4 0.0006
585 ORAL DISCOMFORT 9 0.0006
586 PRODUCT DISTRIBUTION ISSUE 6 0.0006
587 INFUSION SITE EXTRAVASATION 4 0.0006
588 APNOEA 5 0.0006
589 FLANK PAIN 6 0.0006
590 NASAL DRYNESS 4 0.0006
591 SWELLING OF EYELID 4 0.0006
592 SEASONAL ALLERGY 9 0.0006
593 INJECTION SITE WARMTH 13 0.0006
594 UNDERDOSE 46 0.0006
595 HYPOPHAGIA 16 0.0006
596 NAUSEA 494 0.0006
597 CONSTIPATION 136 0.0006
598 BLOOD CALCIUM DECREASED 7 0.0006
599 MUSCLE DISORDER 5 0.0006
600 ANAPHYLACTIC REACTION 34 0.0006
601 GOUT 11 0.0006
602 MYALGIA 104 0.0006
603 BACK PAIN 142 0.0006
604 GASTROOESOPHAGEAL REFLUX DISEASE 49 0.0006
605 GENERALISED TONIC-CLONIC SEIZURE 10 0.0006
606 PNEUMOCYSTIS JIROVECII PNEUMONIA 6 0.0006
607 BONE PAIN 35 0.0006
608 COVID-19 PNEUMONIA 7 0.0006
609 EYE SWELLING 22 0.0006
610 PRODUCT LABEL ISSUE 4 0.0006
611 EPISTAXIS 44 0.0006
612 CEREBRAL HAEMORRHAGE 21 0.0006
613 NEPHROTIC SYNDROME 4 0.0006
614 ECCHYMOSIS 4 0.0006
615 LIMB DISCOMFORT 18 0.0006
616 ENCEPHALITIS 4 0.0006
617 SKIN SWELLING 5 0.0006
618 PLEURAL EFFUSION 35 0.0006
619 FEELING COLD 16 0.0006
620 APHONIA 8 0.0006
621 URINE OUTPUT DECREASED 5 0.0006
622 BLOOD PRESSURE DECREASED 38 0.0006
623 BLOOD CALCIUM INCREASED 5 0.0006
624 CARDIOMEGALY 7 0.0006
625 DRUG ADMINISTERED AT INAPPROPRIATE SITE 6 0.0006
626 APPLICATION SITE REACTION 4 0.0006
627 INCONTINENCE 6 0.0006
628 PNEUMOTHORAX 9 0.0006
629 BRONCHITIS 42 0.0006
630 BALANCE DISORDER 49 0.0006
631 ULCER 9 0.0006
632 GENERALISED OEDEMA 7 0.0006
633 PAIN IN JAW 16 0.0006
634 PHARYNGITIS 7 0.0006
635 LACRIMATION INCREASED 17 0.0006
636 BREAST PAIN 6 0.0006
637 FEAR OF INJECTION 4 0.0006
638 FACIAL PAIN 5 0.0006
639 COVID-19 98 0.0006
640 PAIN OF SKIN 15 0.0006
641 DERMATITIS ALLERGIC 7 0.0006
642 IMPAIRED QUALITY OF LIFE 8 0.0006
643 NEOPLASM MALIGNANT 37 0.0006
644 INJECTION SITE IRRITATION 7 0.0005
645 SYNCOPE 55 0.0005
646 GASTROENTERITIS 8 0.0005
647 DYSPHONIA 32 0.0005
648 ASPARTATE AMINOTRANSFERASE INCREASED 29 0.0005
649 ORAL DISORDER 4 0.0005
650 PHOTOSENSITIVITY REACTION 9 0.0005
651 ANAPHYLACTIC SHOCK 14 0.0005
652 NERVE COMPRESSION 5 0.0005
653 LOSS OF CONSCIOUSNESS 69 0.0005
654 INJECTION SITE PRURITUS 36 0.0005
655 MALNUTRITION 6 0.0005
656 OCULAR DISCOMFORT 6 0.0005
657 GENERAL SYMPTOM 4 0.0005
658 HYPOTENSION 107 0.0005
659 PULMONARY CONGESTION 7 0.0005
660 PULMONARY HYPERTENSION 11 0.0005
661 SPINAL DISORDER 5 0.0005
662 HOSPITALISATION 81 0.0005
663 SCAR 9 0.0005
664 MYOCARDITIS 6 0.0005
665 PANCYTOPENIA 29 0.0005
666 MUSCULOSKELETAL CHEST PAIN 8 0.0005
667 DYSSTASIA 15 0.0005
668 NEUROTOXICITY 9 0.0005
669 VITAMIN D DEFICIENCY 5 0.0005
670 PROCEDURAL PAIN 14 0.0005
671 BLADDER DISORDER 5 0.0005
672 RESPIRATORY TRACT INFECTION 13 0.0005
673 BRAIN INJURY 5 0.0005
674 BLOOD TEST ABNORMAL 7 0.0005
675 MALIGNANT NEOPLASM PROGRESSION 51 0.0005
676 CRYING 18 0.0005
677 PRODUCT USE IN UNAPPROVED INDICATION 122 0.0005
678 DEPRESSED MOOD 26 0.0005
679 BRONCHOSPASM 7 0.0005
680 ALANINE AMINOTRANSFERASE INCREASED 30 0.0005
681 CHEST DISCOMFORT 50 0.0005
682 TREMOR 81 0.0005
683 EAR DISCOMFORT 5 0.0005
684 HYPOXIA 17 0.0005
685 THERAPEUTIC RESPONSE SHORTENED 16 0.0005
686 NEEDLE ISSUE 14 0.0005
687 NERVOUS SYSTEM DISORDER 15 0.0005
688 TENDERNESS 5 0.0005
689 EYE PAIN 27 0.0005
690 THERAPEUTIC PRODUCT EFFECT INCOMPLETE 34 0.0005
691 DYSPNOEA EXERTIONAL 18 0.0005
692 BLOOD SODIUM DECREASED 9 0.0005
693 TRANSFUSION 5 0.0005
694 DEEP VEIN THROMBOSIS 31 0.0005
695 RENAL PAIN 5 0.0005
696 CARDIAC DISORDER 44 0.0005
697 HIP FRACTURE 15 0.0005
698 HAEMATOMA 12 0.0005
699 AGITATION 34 0.0005
700 INJECTION SITE INDURATION 6 0.0005
701 MUSCLE STRAIN 4 0.0005
702 PYELONEPHRITIS 4 0.0005
703 SEPSIS 51 0.0005
704 BEDRIDDEN 6 0.0005
705 HEPATIC FUNCTION ABNORMAL 17 0.0005
706 GROIN PAIN 4 0.0005
707 COLD SWEAT 8 0.0005
708 HAEMATOCRIT DECREASED 9 0.0005
709 LYMPHOCYTE COUNT DECREASED 8 0.0005
710 HERPES ZOSTER 26 0.0005
711 VISION BLURRED 62 0.0005
712 ANAEMIA 86 0.0005
713 COUGH 125 0.0004
714 SWELLING FACE 29 0.0004
715 ANAL INCONTINENCE 4 0.0004
716 SINUS CONGESTION 6 0.0004
717 OROPHARYNGEAL DISCOMFORT 4 0.0004
718 FLUSHING 45 0.0004
719 NASAL CONGESTION 26 0.0004
720 LEUKOCYTOSIS 8 0.0004
721 TOOTHACHE 8 0.0004
722 ATRIAL FIBRILLATION 43 0.0004
723 PALLOR 12 0.0004
724 DRY EYE 22 0.0004
725 ABDOMINAL DISTENSION 46 0.0004
726 RENAL IMPAIRMENT 37 0.0004
727 BONE DISORDER 8 0.0004
728 URINARY INCONTINENCE 13 0.0004
729 METABOLIC ACIDOSIS 14 0.0004
730 SEPTIC SHOCK 19 0.0004
731 RESPIRATORY DISTRESS 12 0.0004
732 INCREASED TENDENCY TO BRUISE 4 0.0004
733 PRODUCT COMPLAINT 11 0.0004
734 IRRITABILITY 26 0.0004
735 BLOOD POTASSIUM INCREASED 7 0.0004
736 HYPOMAGNESAEMIA 6 0.0004
737 HEPATITIS 11 0.0004
738 DERMATITIS 9 0.0004
739 ERYTHEMA MULTIFORME 4 0.0004
740 SQUAMOUS CELL CARCINOMA 4 0.0004
741 CARDIAC FAILURE 34 0.0004
742 FRACTURE 8 0.0004
743 PRODUCT PACKAGING ISSUE 4 0.0004
744 DEHYDRATION 56 0.0004
745 THERAPY INTERRUPTED 30 0.0004
746 EYE INFLAMMATION 4 0.0004
747 BLINDNESS 17 0.0004
748 INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION 75 0.0004
749 LOCALISED INFECTION 10 0.0004
750 DYSURIA 15 0.0004
751 GLOMERULAR FILTRATION RATE DECREASED 5 0.0004
752 BODY TEMPERATURE DECREASED 4 0.0004
753 SPINAL OPERATION 5 0.0004
754 LIMB INJURY 11 0.0004
755 DRUG EFFECT LESS THAN EXPECTED 6 0.0004
756 INFLUENZA 45 0.0004
757 SKIN EXFOLIATION 34 0.0004
758 TOOTH EXTRACTION 5 0.0004
759 OROPHARYNGEAL PAIN 37 0.0004
760 DEATH 344 0.0004
761 HOT FLUSH 30 0.0004
762 RASH ERYTHEMATOUS 19 0.0004
763 ACUTE RESPIRATORY DISTRESS SYNDROME 7 0.0004
764 DRY THROAT 4 0.0004
765 TOOTH ABSCESS 4 0.0004
766 SLUGGISHNESS 4 0.0004
767 HYPONATRAEMIA 22 0.0004
768 INITIAL INSOMNIA 4 0.0004
769 DYSPHAGIA 37 0.0004
770 THYROID DISORDER 6 0.0004
771 INFLUENZA LIKE ILLNESS 32 0.0004
772 LYMPHOMA 6 0.0004
773 EYE DISCHARGE 4 0.0004
774 ANGINA PECTORIS 11 0.0004
775 NODULE 5 0.0004
776 POOR QUALITY PRODUCT ADMINISTERED 4 0.0004
777 MULTIPLE SCLEROSIS RELAPSE 26 0.0004
778 OCULAR HYPERAEMIA 18 0.0004
779 SCRATCH 4 0.0004
780 RESPIRATORY TRACT CONGESTION 6 0.0004
781 DYSGEUSIA 28 0.0004
782 BACTERIAL INFECTION 7 0.0004
783 EYE HAEMORRHAGE 5 0.0004
784 THROMBOSIS 30 0.0004
785 PHOTOPHOBIA 7 0.0004
786 HYPOCALCAEMIA 7 0.0004
787 DRY SKIN 49 0.0004
788 GINGIVAL BLEEDING 5 0.0004
789 GASTROINTESTINAL PAIN 4 0.0004
790 MELAENA 8 0.0004
791 DIVERTICULITIS 10 0.0004
792 KIDNEY INFECTION 7 0.0004
793 ABDOMINAL PAIN LOWER 9 0.0004
794 TRANSIENT ISCHAEMIC ATTACK 12 0.0004
795 BREAST CANCER 33 0.0004
796 HEART RATE IRREGULAR 8 0.0004
797 REBOUND EFFECT 4 0.0004
798 SINUS DISORDER 7 0.0004
799 MITRAL VALVE INCOMPETENCE 4 0.0004
800 MUSCULOSKELETAL DISCOMFORT 6 0.0003
801 HYPOACUSIS 15 0.0003
802 SKIN ULCER 9 0.0003
803 THERAPEUTIC RESPONSE DECREASED 21 0.0003
804 CYSTITIS 11 0.0003
805 ANOSMIA 5 0.0003
806 LIVER FUNCTION TEST ABNORMAL 10 0.0003
807 RENAL DISORDER 16 0.0003
808 HEART RATE INCREASED 34 0.0003
809 HEAD DISCOMFORT 6 0.0003
810 ARRHYTHMIA 16 0.0003
811 PULMONARY MASS 5 0.0003
812 PRODUCTIVE COUGH 16 0.0003
813 PULMONARY OEDEMA 15 0.0003
814 HYPERLIPIDAEMIA 4 0.0003
815 FLUID RETENTION 17 0.0003
816 STAPHYLOCOCCAL INFECTION 11 0.0003
817 PALPITATIONS 39 0.0003
818 GASTROENTERITIS VIRAL 6 0.0003
819 THERAPY CESSATION 17 0.0003
820 EATING DISORDER 7 0.0003
821 INJECTION SITE URTICARIA 8 0.0003
822 SMALL INTESTINAL OBSTRUCTION 4 0.0003
823 CONJUNCTIVITIS 6 0.0003
824 AGRANULOCYTOSIS 6 0.0003
825 CYST 4 0.0003
826 MENTAL DISORDER 14 0.0003
827 CATARACT 19 0.0003
828 ACNE 24 0.0003
829 TRANSAMINASES INCREASED 7 0.0003
830 TOOTH DISORDER 7 0.0003
831 HEPATOTOXICITY 7 0.0003
832 HEART RATE DECREASED 11 0.0003
833 ACUTE RESPIRATORY FAILURE 6 0.0003
834 MOVEMENT DISORDER 10 0.0003
835 DRUG RESISTANCE 8 0.0003
836 HERNIA 6 0.0003
837 UNRESPONSIVE TO STIMULI 8 0.0003
838 MUSCLE TIGHTNESS 5 0.0003
839 EYE DISORDER 10 0.0003
840 FALL 101 0.0003
841 CYTOMEGALOVIRUS INFECTION 5 0.0003
842 ACCIDENTAL OVERDOSE 11 0.0003
843 ACUTE KIDNEY INJURY 46 0.0003
844 PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME 7 0.0003
845 HAIR TEXTURE ABNORMAL 4 0.0003
846 QUALITY OF LIFE DECREASED 4 0.0003
847 CORONARY ARTERY DISEASE 9 0.0003
848 LETHARGY 17 0.0003
849 FOETAL EXPOSURE DURING PREGNANCY 24 0.0003
850 ANGIOEDEMA 13 0.0003
851 ACUTE HEPATIC FAILURE 4 0.0003
852 SKIN LESION 8 0.0003
853 BLOOD PRESSURE FLUCTUATION 7 0.0003
854 HEPATIC CANCER 7 0.0003
855 SWOLLEN TONGUE 9 0.0003
856 BLOOD PRESSURE INCREASED 44 0.0003
857 COORDINATION ABNORMAL 4 0.0003
858 ECZEMA 15 0.0003
859 SPEECH DISORDER 15 0.0003
860 RASH MACULAR 10 0.0003
861 HEAD INJURY 9 0.0003
862 SOMNOLENCE 57 0.0003
863 ISCHAEMIC STROKE 5 0.0003
864 PRODUCT QUALITY ISSUE 38 0.0003
865 VERTIGO 17 0.0003
866 CARDIOGENIC SHOCK 4 0.0003
867 CARDIAC ARREST 23 0.0003
868 COGNITIVE DISORDER 13 0.0003
869 MYELODYSPLASTIC SYNDROME 4 0.0003
870 DRUG INEFFECTIVE 364 0.0003
871 OSTEOMYELITIS 5 0.0003
872 INJECTION SITE HAEMATOMA 4 0.0003
873 HYPOKINESIA 4 0.0003
874 PELVIC PAIN 5 0.0003
875 HYPERGLYCAEMIA 10 0.0003
876 HAEMATOCHEZIA 15 0.0003
877 LIP SWELLING 9 0.0003
878 STEVENS-JOHNSON SYNDROME 6 0.0003
879 CIRCUMSTANCE OR INFORMATION CAPABLE OF LEADING TO MEDICATION ERROR 9 0.0003
880 HYPERHIDROSIS 34 0.0003
881 BLOOD URINE PRESENT 5 0.0003
882 PULMONARY EMBOLISM 25 0.0003
883 FEELING JITTERY 5 0.0003
884 SEIZURE 30 0.0003
885 DRUG INEFFECTIVE FOR UNAPPROVED INDICATION 14 0.0003
886 DISORIENTATION 10 0.0003
887 MULTIPLE SCLEROSIS 12 0.0003
888 DIABETIC KETOACIDOSIS 6 0.0002
889 SPINAL FRACTURE 5 0.0002
890 MENTAL IMPAIRMENT 6 0.0002
891 PRODUCT DOSE OMISSION IN ERROR 7 0.0002
892 CEREBRAL INFARCTION 6 0.0002
893 VENTRICULAR TACHYCARDIA 4 0.0002
894 RENAL FAILURE 32 0.0002
895 URINARY RETENTION 8 0.0002
896 TINNITUS 11 0.0002
897 FEELING ABNORMAL 57 0.0002
898 ACUTE MYOCARDIAL INFARCTION 7 0.0002
899 PSORIASIS 31 0.0002
900 CANDIDA INFECTION 4 0.0002
901 CIRCULATORY COLLAPSE 4 0.0002
902 COMA 11 0.0002
903 HAEMORRHAGE 24 0.0002
904 PRODUCT PRESCRIBING ISSUE 5 0.0002
905 FLATULENCE 13 0.0002
906 EOSINOPHILIA 4 0.0002
907 BLOOD GLUCOSE INCREASED 43 0.0002
908 GASTRITIS 6 0.0002
909 DRUG ERUPTION 4 0.0002
910 GAMMA-GLUTAMYLTRANSFERASE INCREASED 5 0.0002
911 THIRST 4 0.0002
912 RESPIRATORY FAILURE 16 0.0002
913 RESTLESSNESS 8 0.0002
914 LACTIC ACIDOSIS 7 0.0002
915 GASTRIC ULCER 4 0.0002
916 INTENTIONAL DOSE OMISSION 6 0.0002
917 CEREBROVASCULAR ACCIDENT 35 0.0002
918 BLOOD PRESSURE SYSTOLIC INCREASED 4 0.0002
919 UPPER LIMB FRACTURE 4 0.0002
920 PNEUMONIA ASPIRATION 5 0.0002
921 HYPERKALAEMIA 7 0.0002
922 HEPATIC FAILURE 6 0.0002
923 WRONG TECHNIQUE IN PRODUCT USAGE PROCESS 40 0.0002
924 DEVICE BREAKAGE 8 0.0002
925 SKIN BURNING SENSATION 14 0.0002
926 POLLAKIURIA 8 0.0002
927 DEAFNESS 5 0.0002
928 INJECTION SITE MASS 7 0.0002
929 HYPOTHYROIDISM 6 0.0002
930 JOINT INJURY 4 0.0002
931 IMPAIRED WORK ABILITY 4 0.0002
932 EXPIRED PRODUCT ADMINISTERED 6 0.0002
933 MENTAL STATUS CHANGES 5 0.0002
934 FUNGAL INFECTION 6 0.0002
935 RASH MACULO-PAPULAR 4 0.0002
936 HAEMOPTYSIS 5 0.0002
937 ORAL PAIN 4 0.0002
938 EYE PRURITUS 6 0.0002
939 PANCREATITIS ACUTE 4 0.0002
940 DEPRESSED LEVEL OF CONSCIOUSNESS 7 0.0002
941 MULTIPLE ORGAN DYSFUNCTION SYNDROME 5 0.0002
942 SHOCK 4 0.0002
943 PERICARDIAL EFFUSION 4 0.0002
944 DIABETES MELLITUS 13 0.0002
945 BRADYCARDIA 9 0.0002
946 CARDIO-RESPIRATORY ARREST 7 0.0002
947 PANIC ATTACK 6 0.0002
948 CARDIOVASCULAR DISORDER 4 0.0002
949 MOOD SWINGS 5 0.0002
950 DEVICE ISSUE 14 0.0002
951 SEDATION 4 0.0002
952 APPLICATION SITE ERYTHEMA 4 0.0002
953 NEPHROLITHIASIS 7 0.0002
954 INCORRECT DOSE ADMINISTERED BY DEVICE 4 0.0002
955 INJECTION SITE HAEMORRHAGE 12 0.0002
956 INCORRECT DOSE ADMINISTERED 34 0.0001
957 EXTRA DOSE ADMINISTERED 6 0.0001
958 LUNG NEOPLASM MALIGNANT 6 0.0001
959 CHRONIC KIDNEY DISEASE 11 0.0001
960 DEMENTIA 4 0.0001
961 INCORRECT ROUTE OF DRUG ADMINISTRATION 5 0.0001
962 HYPERSOMNIA 4 0.0001
963 CARDIAC FAILURE CONGESTIVE 11 0.0001
964 DEVICE DIFFICULT TO USE 9 0.0001
965 INTESTINAL OBSTRUCTION 5 0.0001
966 UNEVALUABLE EVENT 10 0.0001
967 SKIN IRRITATION 6 0.0001
968 FEMUR FRACTURE 4 0.0001
969 ACCIDENTAL EXPOSURE TO PRODUCT 13 0.0001
970 DISEASE RECURRENCE 6 0.0001
971 MYOCARDIAL INFARCTION 22 0.0001
972 OSTEONECROSIS 4 0.0001
973 RHABDOMYOLYSIS 5 0.0001
974 HAEMATURIA 4 0.0001
975 DEVICE USE ERROR 4 0.0001
976 INTENTIONAL PRODUCT MISUSE 10 0.0001
977 THERAPEUTIC RESPONSE UNEXPECTED 5 0.0001
978 DISTURBANCE IN ATTENTION 6 0.0001
979 GASTROINTESTINAL HAEMORRHAGE 9 0.0001
980 DRUG INTERACTION 17 0.0001
981 EYE IRRITATION 6 0.0001
982 HYPOGLYCAEMIA 5 0.0001
983 TOXICITY TO VARIOUS AGENTS 17 0.0001
984 DYSKINESIA 4 0.0001
985 HALLUCINATION 7 0.0001
986 VAGINAL HAEMORRHAGE 4 0.0001
987 DEVICE DISLOCATION 4 0.0001
988 DEVICE MALFUNCTION 6 0.0001
989 OVERDOSE 17 0.0001
990 NERVOUSNESS 4 0.0001
991 CONVULSION 4 0.0001
992 PROSTATE CANCER 5 0.0001
993 EMOTIONAL DISTRESS 4 0.0000